

Published by
Ministry of Health, Labour and Welfare



Translated by
Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Rifabutin

March 23, 2023

Therapeutic category

Antibiotic preparations acting mainly on acid-fast bacteria

Non-proprietary name

Rifabutin

Safety measure

Precautions should be revised.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Electronic Package Inserts of Prescription Drugs, etc. PSEHB Notification No. 0611-1 by the Director of Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 11, 2021 (New instructions): Revised language is underlined.

Current	Revision
<p>8. IMPORTANT PRECAUTIONS (N/A)</p>	<p>8. IMPORTANT PRECAUTIONS <Tuberculosis> <u>A paradoxical drug reaction may be observed due to the treatment with antitubercular agents including this drug. If worsening of existing tuberculosis or new onset of tuberculosis symptoms is observed after initiating the treatment, whether to continue administration should be determined on the basis of drug susceptibility tests, etc.</u></p>

Note: Designated as a drug requiring preparation of a Drug Guide for Patients

N/A: Not Applicable. No corresponding language is included in the current Precautions.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp